1-10 of 10
Akash Nahar
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Jane N. Winter, Akash Nahar, Eunhee Kim, Patricia Marinello
Journal: Blood
Blood (2021) 138 (Supplement 1): 1379.
DOI: https://doi.org/10.1182/blood-2021-147276
Published: 2021
Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12.
DOI: https://doi.org/10.1182/blood-2020-142565
Published: 2020
Journal Articles

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Pier Luigi Zinzani, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, José S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, DMed Sci, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
DOI: https://doi.org/10.1182/blood-2020-139416
Published: 2020
Journal Articles

Real-World Conditional Survival Analysis of Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma in the US

Kaushal D Desai, PhD MS, Xiaoqin Yang, PhD, Adrienne M Gilligan, PhD, Yeran Li, PhD, Monika Raut, Akash Nahar
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
DOI: https://doi.org/10.1182/blood-2020-136424
Published: 2020
Journal Articles

Healthcare Resource Utilization and Cost in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma Who Received Autologous Stem Cell Transplantation in the US

Xiaoqin Yang, PhD, Kaushal D Desai, PhD MS, Adrienne M Gilligan, PhD, Monika Raut, Akash Nahar
Journal: Blood
Blood (2020) 136 (Supplement 1): 36–37.
DOI: https://doi.org/10.1182/blood-2020-136328
Published: 2020
Journal Articles

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Philippe Armand, Pier Luigi Luigi Zinzani, MD, John Palcza, Jane Anne Healy, Akash Nahar, Patricia Marinello, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA
Journal: Blood
Blood (2019) 134 (Supplement_1): 1548.
DOI: https://doi.org/10.1182/blood-2019-127474
Published: 2019
Journal Articles

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Clinical Trials & Observations
Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (14): 1144–1153.
DOI: https://doi.org/10.1182/blood.2019000324
Published: 2019
Includes: Supplemental data
Journal Articles

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, MD, Robert W. Chen, MD, Hun Ju Lee, MD, Philippe Armand, MD PhD, Nathalie A Johnson, MD PhD, Pauline Brice, MD, John Radford, MD FRCP, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian Von Tresckow, MD, Margaret A. Shipp, MD, Eunhee Kim, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2900.
DOI: https://doi.org/10.1182/blood-2018-99-117045
Published: 2018
Journal Articles

Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

Craig H. Moskowitz, MD, Robert W. Chen, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD, Theodoros P. Vassilakopoulos, MD PhD, Gregory V. Goldmacher, MD PhD MBA, Jianxin Lin, MS, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Gilles Salles, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4085.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.4085.4085
Published: 2017
Journal Articles

Plasma Homocysteine Levels, Methelene TetraHydroFolate Reductase (MTHFR) Polymorphism, and the Risk of Thromboembolism in Children: A Single Institution Experience

Akash Nahar, MD, Yaddanapudi Ravindranath, MBBS, Jeanne M. Lusher, MD, Meera B. Chitlur, MD, Mary Jane Frey, Cynthia Sabo, Madhvi Rajpurkar, MD
Journal: Blood
Blood (2008) 112 (11): 5351.
DOI: https://doi.org/10.1182/blood.V112.11.5351.5351
Published: 2008